Category Archives: spina bifida

Four important points about Nova Cells Institute

cropped-nova-cells-bannerNova Cells Institute has never worked with embryonic or fetal stem cells, and never will. Embryonic and fetal stem cells can produce tumors (These are classified as pluripotent” which means they can form teratomas and other tumors in certain instances such as being injected into the central nervous system). The adult stem cells Nova Cells uses (umbilical cord, Wharton’s Jelly, placenta-derived, and a patient’s own bone marrow) are “multipotent” which limits the body cell types they can become (These stem cells do not form teratomas or such. Some private stem cell clinics in Europe and the US have injected adult stem cells into organs such as kidneys and eyes which caused problems and complications. Nova Cells Institute has never injected stem cells into an organ).
Let’s be very clear about these points and a few others:

(1) Nova Cells was established in 2009. There are other companies that came along later on which use “Nova” in their company title, but these are NOT affiliated in any way with Nova Cells Institute of Mexico (NCIM).

(2) Nova Cells Institute has never used embryonic or fetal stem cells and never will (They can form tumors under certain circumstances).

(3) Nova Cells Institute only uses multipotent adult stem cells derived from umbilical cord blood, Wharton’s Jelly, placental tissue, and a patient’s own bone marrow.

(4) Nova Cells Institute administers stem cells by intravenous drip (On rare occasions Nova Cells affiliated doctors recommend an intrathecal or spinal tap infusion of cells. Everything related to this is spelled out, a process called “informed consent”. Patients who prefer not to do this are given cells by intravenous or IV drip).

Exciting update on Slovakian infant including video

 

    Nova Cell’s Grace Odgers (left) with baby Ondrej and his Mum – April 28, 2017

October 8, 2017

Hello Grace,

We are amazed and sooooo happy that our little Ondrej is still doing better and better with his legs and movement in general.

Not only can he sit by himself and roll on the bed, but also he can STAND on his legs a while!!! I am sending you the video:  https://www.facebook.com/petra.albrechtova.1/videos/1494068703972449/

–  it was 2 days ago!

We are so happy! 6 months ago (before the stem cell treatment) he couldn´t sit, couldn´t turn to his belly and back, but NOW he can do all these things and STAND with our help too!

God bless you and Abel for the stem cells and the amazing work you do!

Thank you from the bottom of our hearts!

Best wishes,

Petra

 

SLOVIA -with border

PREVIOUS UPDATE ON ONDREJ:

Slovakian infant with spina bifida doing things he could never do before (July 10, 2017)

 

 

NOVA CELLS at-a-glance (2 pages)


NCIM promo flyer - COVER - 8-3-2017

https://ncimx.files.wordpress.com/2017/08/ncim-at-a-glance-2-page-document.pdf

 

COMPARING: What sets Nova Cells apart from all other stem cell treatment programs

compare-apples-oranges-free-morguefilehttps://ncimx.wordpress.com/comparing-what-sets-nova-cells-apart-from-all-other-stem-cell-treatment-programs/

Quick read – NCIM Program

Abel working in biocabinetNova Cells Institute of Mexico contracted MDs treat children and adults with umbilical cord blood stem cells and in some instances a patient’s own bone marrow stem cells. MDs who work with Nova Cells also administer its proprietary “Beacon Factor“, a nontoxic compound that greatly enhances stem cell homing, improves circulation, reduces inflammation, improves nerve signal transmission, and steps up the processing of intracellular “junk” by lysosomes (The cells “garbage disposal” system whose malfunctioning is linked to all kinds of neurodegenerative diseases and conditions).

Nova Cells uses only certifiably disease free umbilical cord stem cells and those from Wharton’s Jelly, and sometimes a patient’s own bone marrow stem cells, all of which are processed in Mexico in a state-of-the-art laboratory run by our firm’s director of laboratory services, Dr. Abel Pena (Photo above).

Dr. Pena, who is a biochemist, was trained by a leading US stem cell biologist and maintains the highest levels of safety and hygiene in his lab in Tijuana. In addition, he has pioneered numerous methods for priming stem cells; that is, getting them to respond to chemical signals in target tissues by becoming cells that tend to effect or support healing or relief. Stem cells primed using his methods have produced impressive, sometimes remarkable clinical responses in people with a wide variety of neurologic & other diseases and conditions.

CONTACT: Grace Odgers, PhD cand. – Program educator and patient care coordinator

Phone: 1-562- 916-3410 E-mail: gracepatients@gmail.com

 THE NOVA CELLS DIFFERENCE

https://ncimexico.files.wordpress.com/2016/07/the-nova-cells-difference.pdf

CONDITIONS NOVA CELLS INSTITUTE HAS SUCCESSFULLY TREATED

https://ncimx.wordpress.com/conditions-nova-cells-has-successfully-treated/

 

 

Wharton’s Jelly Stem Cells: safety & more

stem cells from poweredtemplatesADVANTAGES OF WHARTON’S JELLY STEM CELLS ESPECIALLY MESENCYMALS (Designated as WJ-MSC for convenience below) ESPECIALLY WITH RESPECT TO SAFETY

WJ HAS MORE STEM CELLS THAN EITHER BONE MARROW OR ADIPOSE TISSUE

The quantity of mesenchymal stem cells which can typically be obtained from bone marrow is far less than that Wharton’s Jelly: 0.001 to 0.01% mononuclear cells from BM, with 1 g of adipose tissue yielding ~ 5 × 103 stem cells, and Wharton’s jelly 1 to 5 × 104 cells/cm of umbilical cord. In side-by-side comparison studies of MSC from bone marrow adipose tissue and Wharton’s jelly, WJ-MSCs had the highest proliferative capacity.

WJ STEM CELLS ARE MORE PRIMITIVE THAN OTHER ADULT STEM CELL TYPES YET DO NOT PRODUCE TUMORS AND ACTUALLY HAVE ANTI-TUMOR EFFECTS IN VITRO (Lab dish) AND IN VIVO (In living animals & humans)  

WJ-MSC differ from other adult MSCs with respect to the fact they demonstrate far more primitive characteristics e.g., they express embryonic-like stem cell markers including  pluripotency genes, Oct-4, Nanog, and SOX-2 but at levels well below that of embryonic stem (ESC) cells. Despite this, WJ-MSCs do not form tumors (teratomas). This is attributed to the fact that WJ-MS’s have a lower expression of pluripotency genes than embryonic stem cells (ESCs being very pluripotent and by virtue of this are prone to develop teratomas when injected into animals or humans). When WJ-MSCs were injected in immunocompromised and immunodeficient animals they still failed to form tumors.

Also: WJ-MSCs express low levels of the embryonic stem cell pluripotency markers POUF1, NANOG, SOX2 and LIN28, which also plays a role in the fact they do not produce teratomas. WJ-MSCs also synthesize and express several cytokines including IL12A which is associated with the induction of apoptosis (programmed cell death) which is believed to underlie their ability to lyse (eradicate) tumor cells.

Furthermore, the transcriptome of WJ-MSC and ESC differs substantially in that WJ-MSCs demonstrate high expression levels of several tumor suppressor genes and suppresses tumors both in vitro and in vivo. Moreover, large quantities of tumor growth inhibiting cytokines and growth factors are secreted by WJ-MSCs. Also, WJ-MSC cell lysates as well as the conditioned medium they are cultured in strongly inhibited the growth of breast adenocarcinoma, ovarian carcinoma, osteosarcoma, benign neoplastic keloid cells, bladder tumor, and lymphoma cells  in vitro. When WJ-MSC cell lysates and conditioned medium were injected into mammary carcinoma, osteosarcoma, and pancreatic and lung tumors it inhibited their growth and shrank the tumors in vivo .

WJ-MSCs DO NOT CAUSE IMMUNE REJECTION OR ADVERSE REACTIONS  

WJ-MSCs have also been found to be immunoprivileged which is to say they escape rejection or adverse immune reactions. Part of the reason for this lies in the fact WJ-MSCs have low MHC-I levels and an absence of MHC-II expression. And, though they synthesize low amounts of MHC class I, WJ-MSCs have no immunogenicity. Research indicates that this is due to the fact they  do not express costimulatory molecules such as CD 40, CD80, CD86, and also produce high levels of immune response inhibitors such as indoleamine-2,3-dioxygenase (IDO), prostaglandin E2 (PGE2) and leukocyte antigen G6 (HLA-G6).

NOVA CELLS INSTITUTE HARVESTS & MAKES CLINICAL USE OF STEM CELLS ISOLATED FROM (UMBILICAL CORD) WHARTON’S JELLY CELLS: https://ncimx.wordpress.com/2015/03/15/whartons-jelly-stem-cells/

ADDITIONAL REFERENCES – NIH PubMed results (5-1-2016)

Wharton’s Jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-β deposition in an APP/PS1 transgenic mouse model.
Xie ZH, Liu Z, Zhang XR, Yang H, Wei LF, Wang Y, Xu SL, Sun L, Lai C, Bi JZ, Wang XY.
Clin Exp Med. 2016 Feb;16(1):89-98. doi: 10.1007/s10238-015-0375-0. Epub 2015 Jul 19.
PMID: 26188488 [PubMed – in process]
Similar articles

Therapeutic influence of intraperitoneal injection of Wharton’s jelly-derived mesenchymal stem cells on oviduct function and fertility in rats with acute and chronic salpingitis.
Luo HJ, Xiao XM, Zhou J, Wei W.
Genet Mol Res. 2015 Apr 17;14(2):3606-17. doi: 10.4238/2015.April.17.10.
PMID: 25966129 [PubMed – indexed for MEDLINE] Free Article
Similar articles

Effect of human Wharton’s jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells.
Hendijani F, Javanmard ShH, Rafiee L, Sadeghi-Aliabadi H.
Res Pharm Sci. 2015 Mar-Apr;10(2):134-42.
PMID: 26487890 [PubMed] Free PMC Article
Similar articles

Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells.
Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K.
Diabetes. 2015 Feb;64(2):587-92. doi: 10.2337/db14-0656. Epub 2014 Sep 9.
PMID: 25204974 [PubMed – indexed for MEDLINE] Free Article
Similar articles

. The Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis.
Boruczkowski D, Gładysz D, Demkow U, Pawelec K.
Adv Exp Med Biol. 2015;833:23-9. doi: 10.1007/5584_2014_17. Review.
PMID: 25248343 [PubMed – indexed for MEDLINE]
Similar articles

Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance.
Kalaszczynska I, Ferdyn K.
Biomed Res Int. 2015;2015:430847. doi: 10.1155/2015/430847. Epub 2015 Mar 15. Review.
PMID: 25861624 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Undifferentiated Wharton’s Jelly Mesenchymal Stem Cell Transplantation Induces Insulin-Producing Cell Differentiation and Suppression of T-Cell-Mediated Autoimmunity in Nonobese Diabetic Mice.
Tsai PJ, Wang HS, Lin GJ, Chou SC, Chu TH, Chuan WT, Lu YJ, Weng ZC, Su CH, Hsieh PS, Sytwu HK, Lin CH, Chen TH, Shyu JF.
Cell Transplant. 2015;24(8):1555-70. doi: 10.3727/096368914X683016. Epub 2014 Jul 15.
PMID: 25198179 [PubMed – in process]
Similar articles

Effects of Wharton’s jelly-derived mesenchymal stem cells on neonatal neutrophils.
Khan I, Zhang L, Mohammed M, Archer FE, Abukharmah J, Yuan Z, Rizvi SS, Melek MG, Rabson AB, Shi Y, Weinberger B, Vetrano AM.
J Inflamm Res. 2014 Dec 31;8:1-8. doi: 10.2147/JIR.S71987. eCollection 2015.
PMID: 25678809 [PubMed] Free PMC Article
Similar articles

A comparison of Wharton’s jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.
El-Demerdash RF, Hammad LN, Kamal MM, El Mesallamy HO.
Regen Med. 2015;10(7):841-55. doi: 10.2217/rme.15.49. Epub 2015 Nov 6.
PMID: 26541176 [PubMed – in process]
Similar articles

. Comparisons of Differentiation Potential in Human Mesenchymal Stem Cells from Wharton’s Jelly, Bone Marrow, and Pancreatic Tissues.
Kao SY, Shyu JF, Wang HS, Lin CH, Su CH, Chen TH, Weng ZC, Tsai PJ.
Stem Cells Int. 2015;2015:306158. doi: 10.1155/2015/306158. Epub 2015 Jul 29.
PMID: 26294917 [PubMed] Free PMC Article
Similar articles

. Roles of the co-culture of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells with rat pancreatic cells in the treatment of rats with diabetes mellitus.
Wang G, Li Y, Wang Y, Dong Y, Wang FS, Ding Y, Kang Y, Xu X.
Exp Ther Med. 2014 Nov;8(5):1389-1396. Epub 2014 Sep 22.
PMID: 25289028 [PubMed] Free PMC Article
Similar articles

Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation.
Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y.
Int J Mol Med. 2014 Sep;34(3):695-704. doi: 10.3892/ijmm.2014.1821. Epub 2014 Jun 25.
PMID: 24970492 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy.
Woodworth TG, Furst DE.
Arthritis Res Ther. 2014 Jul 30;16(4):113. doi: 10.1186/ar4677.
PMID: 25166210 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus.
Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y.
Stem Cell Res Ther. 2014 Apr 23;5(2):57. doi: 10.1186/scrt446.
PMID: 24759263 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly.
Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R.
Stem Cell Res Ther. 2014 Apr 16;5(2):53. doi: 10.1186/scrt442.
PMID: 24739658 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Therapeutic effect of transplanted human Wharton’s jelly stem cell-derived oligodendrocyte progenitor cells (hWJ-MSC-derived OPCs) in an animal model of multiple sclerosis.
Mikaeili Agah E, Parivar K, Joghataei MT.
Mol Neurobiol. 2014 Apr;49(2):625-32. doi: 10.1007/s12035-013-8543-2. Epub 2013 Aug 28.
PMID: 23982748 [PubMed – indexed for MEDLINE]
Similar articles

Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1.
Zou X, Zhang G, Cheng Z, Yin D, Du T, Ju G, Miao S, Liu G, Lu M, Zhu Y.
Stem Cell Res Ther. 2014 Mar 19;5(2):40. doi: 10.1186/scrt428.
PMID: 24646750 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

. Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.
Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, Gao H, Zhao W, Yan S, Wang Y.
Endocrine. 2014 Mar;45(2):279-87. doi: 10.1007/s12020-013-9984-0. Epub 2013 May 18.
PMID: 23686639 [PubMed – indexed for MEDLINE]
Similar articles

Effect of human Wharton’s jelly mesenchymal stem cell paracrine signaling on keloid fibroblasts.
Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Jeschke MG.
Stem Cells Transl Med. 2014 Mar;3(3):299-307. doi: 10.5966/sctm.2013-0120. Epub 2014 Jan 16.
PMID: 24436441 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Human Wharton’s jelly mesenchymal stem cells promote skin wound healing through paracrine signaling.
Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Tien CH, Jeschke MG.
Stem Cell Res Ther. 2014 Feb 24;5(1):28. doi: 10.1186/scrt417.
PMID: 24564987 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

. Characterization of hepatic markers in human Wharton’s Jelly-derived mesenchymal stem cells.
Buyl K, De Kock J, Najar M, Lagneaux L, Branson S, Rogiers V, Vanhaecke T.
Toxicol In Vitro. 2014 Feb;28(1):113-9. doi: 10.1016/j.tiv.2013.06.014. Epub 2013 Jun 29.
PMID: 23820183 [PubMed – indexed for MEDLINE]
Similar articles

Human Wharton’s Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with hair growth.
Sabapathy V, Sundaram B, V M S, Mankuzhy P, Kumar S.
PLoS One. 2014 Apr 15;9(4):e93726. doi: 10.1371/journal.pone.0093726. eCollection 2014.
PMID: 24736473 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Stem cells from umbilical cord Wharton’s jelly from preterm birth have neuroglial differentiation potential.
Messerli M, Wagner A, Sager R, Mueller M, Baumann M, Surbek DV, Schoeberlein A.
Reprod Sci. 2013 Dec;20(12):1455-64. doi: 10.1177/1933719113488443. Epub 2013 May 13.
PMID: 23670950 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Wharton’s jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction.
Zhang W, Liu XC, Yang L, Zhu DL, Zhang YD, Chen Y, Zhang HY.
Coron Artery Dis. 2013 Nov;24(7):549-58. doi: 10.1097/MCA.0b013e3283640f00.
PMID: 23892469 [PubMed – indexed for MEDLINE]
Similar articles

Reduction of fibrosis in dibutyltin dichloride-induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton’s jelly.
Zhou CH, Li ML, Qin AL, Lv SX, Wen-Tang, Zhu XY, Li LY, Dong Y, Hu CY, Hu DM, Wang SF.
Pancreas. 2013 Nov;42(8):1291-302. doi: 10.1097/MPA.0b013e318296924e.
PMID: 24152954 [PubMed – indexed for MEDLINE]
Similar articles

Human Wharton’s jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells.
Du T, Zou X, Cheng J, Wu S, Zhong L, Ju G, Zhu J, Liu G, Zhu Y, Xia S.
Stem Cell Res Ther. 2013 Jun 4;4(3):59. doi: 10.1186/scrt215.
PMID: 23734757 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Higher propensity of Wharton’s jelly derived mesenchymal stromal cells towards neuronal lineage in comparison to those derived from adipose and bone marrow.
Balasubramanian S, Thej C, Venugopal P, Priya N, Zakaria Z, Sundarraj S, Majumdar AS.
Cell Biol Int. 2013 May;37(5):507-15. doi: 10.1002/cbin.10056. Epub 2013 Feb 18.
PMID: 23418097 [PubMed – indexed for MEDLINE]
Similar articles

Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton’s jelly and umbilical cord.
Manochantr S, U-pratya Y, Kheolamai P, Rojphisan S, Chayosumrit M, Tantrawatpan C, Supokawej A, Issaragrisil S.
Intern Med J. 2013 Apr;43(4):430-9. doi: 10.1111/imj.12044.
PMID: 23176558 [PubMed – indexed for MEDLINE]
Similar articles

. Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications.
Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C.
Curr Stem Cell Res Ther. 2013 Mar;8(2):144-55. Review.
PMID: 23279098 [PubMed – indexed for MEDLINE]
Similar articles

Proangiogenic features of Wharton’s jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels.
Choi M, Lee HS, Naidansaren P, Kim HK, O E, Cha JH, Ahn HY, Yang PI, Shin JC, Joe YA.
Int J Biochem Cell Biol. 2013 Mar;45(3):560-70. doi: 10.1016/j.biocel.2012.12.001. Epub 2012 Dec 12.
PMID: 23246593 [PubMed – indexed for MEDLINE]
Similar articles

Mesenchymal stem cells isolated from peripheral blood and umbilical cord Wharton’s jelly.
Trivanović D, Kocić J, Mojsilović S, Krstić A, Ilić V, Djordjević IO, Santibanez JF, Jovcić G, Terzić M, Bugarski D.
Srp Arh Celok Lek. 2013 Mar-Apr;141(3-4):178-86.
PMID: 23745340 [PubMed – indexed for MEDLINE] Free Article
Similar articles

Wharton’s jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report.
López Y, Lutjemeier B, Seshareddy K, Trevino EM, Hageman KS, Musch TI, Borgarelli M, Weiss ML.
Curr Stem Cell Res Ther. 2013 Jan;8(1):46-59.
PMID: 23270633 [PubMed – indexed for MEDLINE]
Similar articles

Perspectives of employing mesenchymal stem cells from the Wharton’s jelly of the umbilical cord for peripheral nerve repair.
Ribeiro J, Gartner A, Pereira T, Gomes R, Lopes MA, Gonçalves C, Varejão A, Luís AL, Maurício AC.
Int Rev Neurobiol. 2013;108:79-120. doi: 10.1016/B978-0-12-410499-0.00004-6. Review.
PMID: 24083432 [PubMed – indexed for MEDLINE]
Similar articles

Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis.
Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, Wu CH, Lin WY, Cheng SM.
PLoS One. 2013 Aug 22;8(8):e72604. doi: 10.1371/journal.pone.0072604. eCollection 2013.
PMID: 23991127 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Comparison of mesenchymal stem cells derived from fat, bone marrow, Wharton’s jelly, and umbilical cord blood for treating spinal cord injuries in dogs.
Ryu HH, Kang BJ, Park SS, Kim Y, Sung GJ, Woo HM, Kim WH, Kweon OK.
J Vet Med Sci. 2012 Dec;74(12):1617-30. Epub 2012 Aug 9.
PMID: 22878503 [PubMed – indexed for MEDLINE] Free Article
Similar articles

Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton’s Jelly mesenchymal stem cells after myocardial infarction.
Zhang J, Chen GH, Wang YW, Zhao J, Duan HF, Liao LM, Zhang XZ, Chen YD, Chen H.
Chin Med J (Engl). 2012 Oct;125(19):3472-8.
PMID: 23044308 [PubMed – indexed for MEDLINE] Free Article
Similar articles

Immune characterization of mesenchymal stem cells in human umbilical cord Wharton’s jelly and derived cartilage cells.
Liu S, Yuan M, Hou K, Zhang L, Zheng X, Zhao B, Sui X, Xu W, Lu S, Guo Q.
Cell Immunol. 2012 Jul-Aug;278(1-2):35-44. doi: 10.1016/j.cellimm.2012.06.010. Epub 2012 Jul 16.
PMID: 23121974 [PubMed – indexed for MEDLINE]
Similar articles

Human umbilical cord Wharton’s jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells.
Subramanian A, Shu-Uin G, Kae-Siang N, Gauthaman K, Biswas A, Choolani M, Bongso A, Chui-Yee F.
J Cell Biochem. 2012 Jun;113(6):1886-95. doi: 10.1002/jcb.24057.
PMID: 22234854 [PubMed – indexed for MEDLINE]
Similar articles

Comparison of human amniotic fluid-derived and umbilical cord Wharton’s Jelly-derived mesenchymal stromal cells: Characterization and myocardial differentiation capacity.
Bai J, Hu Y, Wang YR, Liu LF, Chen J, Su SP, Wang Y.
J Geriatr Cardiol. 2012 Jun;9(2):166-71. doi: 10.3724/SP.J.1263.2011.12091.
PMID: 22916064 [PubMed] Free PMC Article
Similar articles

Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients.
Ma L, Zhou Z, Zhang D, Yang S, Wang J, Xue F, Yang Y, Yang R.
Thromb Haemost. 2012 May;107(5):937-50. doi: 10.1160/TH11-08-0596. Epub 2012 Mar 8.
PMID: 22398715 [PubMed – indexed for MEDLINE]
Similar articles

Comparison of chemokine and receptor gene expression between Wharton’s jelly and bone marrow-derived mesenchymal stromal cells.
Balasubramanian S, Venugopal P, Sundarraj S, Zakaria Z, Majumdar AS, Ta M.
Cytotherapy. 2012 Jan;14(1):26-33. doi: 10.3109/14653249.2011.605119. Epub 2011 Nov 18.
PMID: 22091833 [PubMed – indexed for MEDLINE]
Similar articles

Wharton’s Jelly stem cells: future clinical applications.
Taghizadeh RR, Cetrulo KJ, Cetrulo CL.
Placenta. 2011 Oct;32 Suppl 4:S311-5. doi: 10.1016/j.placenta.2011.06.010. Epub 2011 Jul 6. Review.
PMID: 21733573 [PubMed – indexed for MEDLINE]
Similar articles

Neuronal plasticity of human Wharton’s jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells.
Datta I, Mishra S, Mohanty L, Pulikkot S, Joshi PG.
Cytotherapy. 2011 Sep;13(8):918-32. doi: 10.3109/14653249.2011.579957. Epub 2011 Jun 22.
PMID: 21696238 [PubMed – indexed for MEDLINE]
Similar articles

Wharton’s jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.
Anzalone R, Lo Iacono M, Loria T, Di Stefano A, Giannuzzi P, Farina F, La Rocca G.
Stem Cell Rev. 2011 Jun;7(2):342-63. doi: 10.1007/s12015-010-9196-4. Review.
PMID: 20972649 [PubMed – indexed for MEDLINE]
Similar articles

Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes.
Zhou C, Yang B, Tian Y, Jiao H, Zheng W, Wang J, Guan F.
Cell Immunol. 2011;272(1):33-8. doi: 10.1016/j.cellimm.2011.09.010. Epub 2011 Sep 29.
PMID: 22004796 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Video: Little boy with spina bifida is now moving the toes on both his feet

Rikky Foresman is a little boy with spina bifida who had his first stem cell treatment with Nova Cells Institute during early 2014. Last month (March 2016) he underwent another treatment with laboratory primed umbilical cord stem cells and NCIM’s unique & proprietary “Beacon Factor”. It has now been less than 3 weeks since Rikky’s treatment, and on March 29 (2016) his father posted a video of the boy moving the toes on both his feet on the family’s “Blazin’ for Rikky” Facebook page at https://www.facebook.com/BlazinforRikky/?fref=nf

It should also be noted that Rikky began feeling temperature changes in his legs and feet the very next day following his treatment (while at the beach).

 FORESMAN video - late March 2016

HD
This link is to past stories on Rikky that have been posted on this website:

NEW video: Dryden Corvers shows off his physical and motor prowess!

Dryden Colverhttps://www.youtube.com/watch?v=k4x7LdrM3vU&feature=youtu.be

The Rikky Foresman saga continues: “Rikky is standing!”

Blazin for Rikky – March 3, 2014

https://www.facebook.com/BlazinforRikky

Rikky is standing!!!

Rikky is standing - March 3 2014

READ MORE ON RIKKY FORESMAN AT http://ncimx.wordpress.com/?s=Foresman 

Update on Ryan Neighbors by her Mum, Shelly (Includes a link to a recent video of Ryan and 4 photos)

New video of Ryan standing ALMOST all on her own:

https://www.facebook.com/photo.php?v=10202462548192683&l=1269382276310712012

We are starting fundraising again this weekend. and our goal is to be back (to Nova Cells) by this summer/fall

Ryan’s core strength is MIND BLOWING. She’s breathing so much better and eating all sorts of different foods. She is also writing her name and is able to stabilize her  trunk and balance when in a crawling position and when standing. Her legs aren’t doing as much as we hoped, BUT she has gained so much strength in her core and in other places I never even thought of it helping her legs. I know for a fact we wouldn’t be where we are today without your help and the stem cells. Hopefully a 2nd round will do much more.

We love you guys and can’t wait to see you again.

GOD IS GOOD. Love you guys MUCHO!!!!

Shelly Neighbors

AND IN A FEBRURY 10, 2014 EMAIL SHELLY HAD THIS TO SHARE WITH NCIM’S GRACE:

I have so much to tell you and show you!

Ryan is moving her legs on her own CONTROLLED!! We’re not walking – but this is a step in the right direction.

Not only that – but she recently had a sleep study to check on her central sleep apnea.  Before stem cells, she was having 66 episodes per night. After we Only had 7! They are thinking about taking her off her oxygen!

We hope to see you all again before this fall. I have videos to send but I’m at the gym. I send them when I get home. We love you and hope all is well.

Xoxo

Shelly Neighbors

Image

Image

Image

Image

2 new videos of little Alejandra (spina bifida) reveal impressive progress!

Nova’s Cells Institute (NCIM) doctors, scientists and other participants in its ever-evolving stem cell medicine program celebrate each and every improvement that surfaces in the people it treats. What follows below are links to 2 videos of little Alejandra which showcase the truly impressive post-treatment progress she has made. These videos were posted to Alejandra’s Facebook page by her Mum whose comments follow the link to each video.

Join NCIM as it celebrates little Alejandra’s ongoing journey to betterment and her recent improvements!

https://www.facebook.com/photo.php?v=508529795910803 (2 minutes, 38 seconds)

Antonella’s comment about this video of her daughter, Alejandra: 1 month post stem cells…I so wish I had a video of what she was doing before stem cells because you would not believe this progress…THANK YOU NOVA CELLS, MEXICO!

https://www.facebook.com/photo.php?v=508520542578395 (1 minute, 7 seconds)

Antonella’s comment about this video of her daughter, Alejandra This is how she is moving now…only 1 week after stem cells…THANK YOU NOVA CELLS, MEXICO! — at March of Dimes Canada.

 

Samantha Stiles benefits greatly from NCIM stem cell treatment

JOY - FREE MOREGUEFILE IMAGESamantha “Sammie” Stiles, age 3 at the time of her treatment for spina bifida on 7-4-2012

Little Samantha came to NCIM wearing braces and using crutches to get about which made it possible for her to walk albeit with great difficulty.

In the months following her treatment by NCIM doctors using primed stem cells Samantha’s mother Jennifer reported she is walking more independently and appears to have gained strength in her legs. She added that Samantha “..walks often holding onto my hand or her little toy cart which she was not strong enough to do, she has a lot more confidence. I feel like she has gained sensation further down her legs. She says she can feel her great toes and she tells me she has to go to the bathroom more often like she has gained some sort of feeling. We have had to move her crutches up 3 notches because she has grown taller. I haven’t noticed any more ankle strength but more muscle tone and strength in her legs and now is standing taller & straighter with more confidence without her braces”.

More recently, Jennifer Stiles wrote NCIM that Samantha is has been getting ever stronger and as-a-result does not use her crutches at all anymore and  is now walking and dancing all over the place using only her little braces. The Stile family are hoping that Samantha will be able get rid of her braces in the near future.

View this video of Samantha walking independently (note the huge grin)
Samantha’s video

If you need a viewer, here is a free download that we at NCIM used to watch this video:
Vidolan.org/index.html

OLYMPUS DIGITAL CAMERAWant to know more about NCIM and its stem cell treatment program for neurologic issues in children and adults? Call NCIM’s US information line at 1-562-916-3410 (10 am to 7 pm Pacific Time, Monday through Friday) or email NCIM patient care facilitator/educator Grace by e-mail at gracepatients@gmail.com.

Gabe Smith (Spina Bifida): Making rapid progress

My name is Kristin Smith and my 2 ½ year old son, Gabe, has myelomeningocele type spina bifida affecting the L3-L4 region of his spine. He also has a VP shunt in place. When he was 1 ½ years old we took him to China for his first stem cell treatment where he received eight (8) intravenous IV treatments with umbilical cord stem cells along with acupuncture, physical therapy, fire cupping and massage. The cost was $30,000 USD. Prior to this treatment Gabe was unable to use his legs and had low hip movement as well as low sensation and poor blood flow in his legs and feet. Following his treatment he was able to move his hips enough to use an RGO brace (which basically supports his legs and moves them once he initiates movement with his hips) that allows him to walk with a walker. In addition, he had greater sensation to his knees and was able to support himself on his knees while holding onto something. He also experienced more sensation in his penis.

In May 2012 we went to Tijuana, Mexico for his second stem cell treatment with Nova Cells Institute (NCIM). We had heard many wonderful things about this group especially with regard to the rapid results that families were seeing in their spina bifida-afflicted children following treatment with Nova Cell’s primed stem cells. At the same time we also heard many negative things about the north Baja area, as I’m sure most people from the States have, e.g., violence, kidnapping, dirty, dangerous, etc. We went despite the rumors and are so thankful that we did! To our surprise Tijuana is very clean, full of nice people and a lot of uniformed young children walking around and playing after school. We ate in a local restaurant around 8 pm and never for a second felt insecure or in any danger whatsoever. It was the opposite of what we were told by well meaning friends and other who were basically just speculated wildly. We had great food and while waiting to cross the border (back into the US) were able to buy some great souvenirs from the local people who were working hard to support their families.

As for the treatment itself, NCIM’s Grace and Abel picked us up at our hotel in San Diego and were simply the best hosts you could ever hope to find. Once at the clinic, our son did not cry when we handed him to the doctor because Abel was in the OR with him throughout the entire procedure which made him feel totally at ease. The procedure went perfectly and his legs almost immediately warmed up (better blood flow) which made both he and us so very happy. Grace stayed with us during Gabe’s treatment and recovery, comforting us and answering all our questions, and then went with my husband to get some food. Amazingly, after they returned with the food our big boy ate an entire plate of chicken and rice thirty. Hardly (30) minutes had elapsed since his treatment!

Within the first week after Gabe’s treatment we began seeing improvements. Among them:

☺He was able to consistently crawl while pulling his legs underneath himself.

☺He was able to climb up 10 stairs without help, pulling his legs up all by himself.

☺ Also, his therapist realized that he was no longer relying on his RGO to move his legs, but was using his own leg muscles to walk!

All of these gains represented firsts for Gabe, mind you.

Now it has been almost two (2) months since our treatment and he is moving his legs from the knee, and has a lot more strength. He has more sensation further down his legs and is a lot faster and more mobile. Also, he is able to move around during play in ways that he never could before.

I would be remiss if I did not point out the vast difference between Gabe’s treatments in China and then Mexico (Nova Cells): The Chinese stem cell & other treatments took place over many weeks, cost $30K USD, and produced some modest physical improvements. The Nova Cell’s primed stem cell treatment took a single day, cost far less than the Chinese treatment, and produced very impressive improvements in Gabe literally coming out of the gate and continuing to this very day.

To say we are all more than delighted with Nova Cells and the wonderful people who make up the NCIM family is an understatement.

Readers should feel free to contact me at kristinsmith32@gmail.com but please put something in the subject line pertaining to stem cells so I do not think it is spam.

JULY 21, 2012 VIDEO OF GABE: http://www.youtube.com/watch?v=u4xsGl926yo&sns=fb (28 seconds)

ADDITIONAL VIDEOS OF GABE CAN BE FOUND BY CLICKING THIS LINK: https://www.youtube.com/results?search_query=mospina85

REGULAR UPDATES ON GABE’S PROGRESS ARE POSTED TO “GABE WILL WALK” ON FACEBOOK: https://www.facebook.com/#!/GabeWillWalk?fref=ts (NOTE: You will need a Facebook account to access this community page. If you do not have a Facebook account you can easily set one up by clicking this link https://www.facebook.com/r.php?locale=en_US)

Want to know more about NCIM and its stem cell treatment program for neurologic issues in children and adults? Call NCIM’s US information line at 1-562-916-3410 (10 am to 7 pm Pacific Time, Monday through Friday) or email NCIM patient care facilitator/educator Grace Pena by e-mail at gracepatients@gmail.com.